1 Division of Metabolism, Department of Paediatrics, University of Zürich, Zürich, Switzerland 2 Affiliated with the Neuroscience Centre Zurich ZNZ, Zürich, Switzerland 3 Affiliated with the Children's Research Centre CRC, Zürich, Switzerland.
4 Department of Neurology, University Hospital of Zurich, Zürich, Switzerland.
Brain. 2015 Oct;138(Pt 10):2948-63. doi: 10.1093/brain/awv224. Epub 2015 Aug 14.
Tyrosine hydroxylase catalyses the hydroxylation of L-tyrosine to l-DOPA, the rate-limiting step in the synthesis of catecholamines. Mutations in the TH gene encoding tyrosine hydroxylase are associated with the autosomal recessive disorder tyrosine hydroxylase deficiency, which manifests phenotypes varying from infantile parkinsonism and DOPA-responsive dystonia, also termed type A, to complex encephalopathy with perinatal onset, termed type B. We generated homozygous Th knock-in mice with the mutation Th-p.R203H, equivalent to the most recurrent human mutation associated with type B tyrosine hydroxylase deficiency (TH-p.R233H), often unresponsive to l-DOPA treatment. The Th knock-in mice showed normal survival and food intake, but hypotension, hypokinesia, reduced motor coordination, wide-based gate and catalepsy. This phenotype was associated with a gradual loss of central catecholamines and the serious manifestations of motor impairment presented diurnal fluctuation but did not improve with standard l-DOPA treatment. The mutant tyrosine hydroxylase enzyme was unstable and exhibited deficient stabilization by catecholamines, leading to decline of brain tyrosine hydroxylase-immunoreactivity in the Th knock-in mice. In fact the substantia nigra presented an almost normal level of mutant tyrosine hydroxylase protein but distinct absence of the enzyme was observed in the striatum, indicating a mutation-associated mislocalization of tyrosine hydroxylase in the nigrostriatal pathway. This hypomorphic mouse model thus provides understanding on pathomechanisms in type B tyrosine hydroxylase deficiency and a platform for the evaluation of novel therapeutics for movement disorders with loss of dopaminergic input to the striatum.
酪氨酸羟化酶催化 L-酪氨酸羟化为 l-DOPA,这是儿茶酚胺合成的限速步骤。编码酪氨酸羟化酶的 TH 基因突变与常染色体隐性遗传障碍酪氨酸羟化酶缺乏症有关,该疾病表现出从婴儿帕金森病和 DOPA 反应性肌张力障碍(也称为 A 型)到围产期发病的复杂脑病(称为 B 型)等不同表型。我们生成了携带突变 Th-p.R203H 的纯合 Th 基因敲入小鼠,该突变相当于与 B 型酪氨酸羟化酶缺乏症(TH-p.R233H)相关的最常见人类突变,通常对 l-DOPA 治疗无反应。Th 基因敲入小鼠表现出正常的生存和进食,但存在低血压、运动减少、运动协调能力降低、宽基步态和僵住。这种表型与中枢儿茶酚胺逐渐丧失以及运动障碍的严重表现有关,表现出昼夜波动,但不能通过标准 l-DOPA 治疗改善。突变型酪氨酸羟化酶不稳定,对儿茶酚胺的稳定作用不足,导致 Th 基因敲入小鼠脑酪氨酸羟化酶免疫反应性下降。事实上,黑质呈现出几乎正常水平的突变型酪氨酸羟化酶蛋白,但纹状体中观察到该酶的明显缺失,表明酪氨酸羟化酶在黑质纹状体通路中存在与突变相关的定位错误。因此,这种低功能小鼠模型为了解 B 型酪氨酸羟化酶缺乏症的病理机制提供了帮助,并为评估新型治疗药物提供了平台,这些药物用于治疗因纹状体多巴胺能输入缺失而导致的运动障碍。